Exploring the melanoma survivorship experience: a qualitative study

Abstract

Cutaneous melanomas are the fifth most common cancer in the United States and the United Kingdom, with a 5-year relative survival of 87-93%.1,2 Targeted and immune checkpoint therapies have further expanded the number of advanced melanoma survivors. Cancer survivorship recommendations have been published by Macmillan Cancer Support; yet programs for melanoma survivors in the US are still in their infancy.3 We aimed to explore experiences and challenges that US patients diagnosed with melanoma experienced in a tertiary cancer centre using in-depth interviews.